LogicBio announces pricing of public offering (1138369)
October 01 2020 - 8:40AM
UK Regulatory
Arix Bioscience PLC (ARIX)
LogicBio announces pricing of public offering
01-Oct-2020 / 14:40 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Arix Bioscience plc
LogicBio announces pricing of public offering
LONDON, 01 October 2020: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global
venture capital company focused on investing in and building breakthrough
biotech companies, today notes that its portfolio company LogicBio
Therapeutics, Inc. (NASDAQ: LOGC) ("LogicBio"), has announced the pricing of
its underwritten public offering in the United States of 7,000,000 shares of
common stock, at a public offering price of $6.00 per share, for total gross
proceeds of approximately $42.0 million, before deducting underwriting
discounts and commissions and offering expenses payable by LogicBio. In
addition, LogicBio has granted the underwriters a 30-day option to purchase
up to an additional 1,050,000 shares of common stock, at the public offering
price less underwriting discounts and commissions. The offering is expected
to close on 5 October 2020, subject to the satisfaction of customary closing
conditions.
Arix has agreed to invest $3.0 million in the offering and retains a stake
of 9.4% in LogicBio.
The shares of common stock described above are being offered by LogicBio
pursuant to an effective shelf registration statement on Form S-3 (File No.
333-234735), which was declared effective by the U.S. Securities and
Exchange Commission ("SEC") on 25 November 2019. A preliminary prospectus
supplement related to the offering was filed with the SEC on 30 September
2020. The final prospectus supplement related to the offering will be filed
with the SEC. When available, you may obtain copies of the final prospectus
supplement and the accompanying prospectus from: Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, NY
10022, by telephone: +1 (877) 821-7388, or by email:
Prospectus_Department@Jefferies.com, Barclays Capital Inc., c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone:
+1 (888) 603-5847, or email: Barclaysprospectus@broadridge.com, or William
Blair & Company, L.L.C., Attention: Prospectus Department, 150 North
Riverside Plaza, Chicago, IL 60606, or by email at
prospectus@williamblair.com or by telephone at +1-800-621-0687. Electronic
copies of the final prospectus supplement and the accompanying prospectus
will also be available on the website of the SEC at www.sec.gov [1]. For the
avoidance of doubt, such prospectus will not constitute a "prospectus" for
the purposes of Directive 2003/71/EC (and amendments thereto, including
Directive 2010/73/EU, to the extent implemented in each relevant EU member
state) and will not have been reviewed by any competent authority in any EU
member state.
This press release does not constitute an offer to sell or a solicitation of
an offer to buy the securities in the offering, nor shall there be any sale
of these securities in any jurisdiction in which an offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of such jurisdiction.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
T: +44 (0) 203 922 0891
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing
in and building breakthrough biotech companies around cutting edge advances
in life sciences. We collaborate with exceptional entrepreneurs and provide
the capital, expertise and global networks to help accelerate their ideas
into important new treatments for patients. As a listed company, we are able
to bring this exciting growth phase of our industry to a broader range of
investors.
For more information please visit: www.arixbioscience.com [2]
ISIN: GB00BD045071
Category Code: MSCM
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
Sequence No.: 85286
EQS News ID: 1138369
End of Announcement EQS News Service
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=9adf90716a79391bb60d3fe285736534&application_id=1138369&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1138369&site_id=vwd&application_name=news
(END) Dow Jones Newswires
October 01, 2020 09:40 ET (13:40 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024